Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain

Open access
Abraldes, Maximino J., Calvo, Pilar, Gámez Lechuga, María, Merino, María, Martín Lorenzo, Teresa, Maravilla-Herrera, Paulina, Gil Jiménez, Beatriz, Ruiz-Moreno, José M. · 2024 · Ophthalmology and Therapy

Abstract

INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients' and their families. The aim of this study was to evaluate the socio-economic burden of nAMD in Spain. METHODS: The annual cost per patient with nAMD was estimated for the first, second, and third year (or beyond) of treatment since diagnosis. Several cost categories were considered including direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labor productivity losses (LPL), and intangible costs (IC) related to loss of quality of life. The average annual cost per patient was estimated by assigning a unit price or financial proxy to the resources consumed per patient. Reference year of costs was 2021. RESULTS: The mean annual cost of nAMD was estimated at €17,265, €15,403, and €14,465 per patient in the first, second, and third year of treatment after diagnosis. There was an additional one-off cost of €744 associated with the diagnosis of nAMD. DHC accounted for most of the total annual cost per patient independent of the year of treatment since diagnosis (48% in year 1; 42% in year 2; 39% in year 3). Similarly, DNHC had an important contribution to the total costs (32% in year 1; 35% in year 2; 37% in year 3), followed by IC (20% in year 1; 23% in year 2; 24% in year 3), while the contribution of patients' LPL was minimal. CONCLUSION: This study estimated a high economic burden associated with nAMD for patients and their families, the healthcare system, and society at large. There is a need to improve the management of these patients to reduce the impact of nAMD disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40123-024-00960-9

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Total costs per patient stratified by year since diagnosis (€2021). Error bars represent the results of the sensitivity analysis
Fig. 1 Total costs per patient stratified by year since diagnosis (€2021). Error bars represent the results of the sensitivity analysisCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. NICE. Age-related macular degeneration: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018. PMID: 29400919.

Cited by

See all 6

Metadata

Authors
Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M.
Affiliations
  • Complejo Hospitalario Universitario de Santiago (ES)
  • Hospital Universitario Miguel Servet (ES)
  • Weber (ES)
Corresponding author
Merino, María
Venue
Ophthalmology and Therapy
Published
2024-05-21
Volume
13
Issue
7
Pages
1925-1935
ISSN
  • 2193-6528 (ISSN-L)
  • 2193-8245
OpenAlex
W4398156621
Cited by
6
References
21
Citations by year
2026: 4 · 2025: 1 · 2024: 1
FWCI
2.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Ophthalmology and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Roche Farma S.A.
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
neovascular age-related macular degeneration, economic burden of disease, health care costs, labor productivity loss, quality of life, vision loss, Spain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain. https://app.cochat.ai/papers/10.1007/s40123-024-00960-9
The paper
Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M. (2024). Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-024-00960-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.